Clinical Trial

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2023-03-24; most recent amendment 2025-06-23.
Status change: Recruiting → Active, Not Recruiting 2024-12-17
Status change: Not Yet Recruiting → Recruiting 2023-08-15
Trial Details
NCT Number NCT05786573
Lead Sponsor Zenas BioPharma (USA), LLC
Conditions Warm Autoimmune Hemolytic Anemia
Enrollment 134 participants
Start Date 2023-09-25
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-25